J.Jpn. Surg. Soc.
ISSN 1880-1129

[Abstract] [Full Text HTML] [Full Text PDF] （in Japanese / 869KB） [Members Only]

J.Jpn. Surg. Soc.. 120(1): 44-50, 2019

Feature topic

CLINICAL FEATURES AND PREVENTION OF SURGICAL SITE INFECTION IN CASES OF INFLAMMATORY BOWEL DISEASE

1) Department of Inflammatory Bowel Disease, Division of Surgery, Hyogo College of Medicine, Nishinomiya, Japan
2) Division of Infection Control and Prevention, Hyogo College of Medicine, Nishinomiya, Japan
3) Nakano Clinic, Toyonaka, Japan

Motoi Uchino1), Hiroki Ikeuchi1), Yoshio Takesue2), Hiroki Nakano3)

Patients with inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn’s disease as representative conditions, have risk factors for surgical site infections (SSIs), such as malnutrition, anemia, and immunosuppressive status. Although the rate of occurrence of SSIs in IBD cases appears high, the rates in cases of elective surgery are similar. On the other hand, in dirty/infected, severe disease, or urgent/emergency surgery cases, the incidence rate increases sharply. Surgery for IBD often requires a staged operation to avoid anastomosis or a complex procedure for the prevention of surgical mortality and morbidity. Recently, immunosuppressive drugs including corticosteroids, thiopurines, calcineurin inhibitors, and biologics have been recommended for use as treatment prior to surgery according to disease severity. Although some controversy remains, each of these immunosuppressive drugs except for corticosteroids appear safe during the postoperative course.

<< To previous pageTo next page >>

To read the PDF file you will need Adobe Reader installed on your computer.